Citigroup’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$216M Buy
346,637
+161,946
+88% +$110M 0.07% 240
2026
Q1
$143M Sell
184,691
-60,644
-25% -$46.4M 0.06% 292
2025
Q4
$189M Buy
245,335
+107,144
+78% +$72.8M 0.08% 215
2025
Q3
$77.7M Sell
138,191
-46,055
-25% -$26M 0.03% 464
2025
Q2
$96.7M Sell
184,246
-1,326
-0.7% -$740K 0.05% 357
2025
Q1
$118M Buy
185,572
+49,128
+36% +$33.8M 0.06% 280
2024
Q4
$97.2M Sell
136,444
-18,514
-12% -$15.5M 0.06% 290
2024
Q3
$163M Buy
154,958
+6,920
+5% +$7.7M 0.09% 183
2024
Q2
$156M Sell
148,038
-6,154
-4% -$5.97M 0.1% 180
2024
Q1
$148M Buy
154,192
+37,371
+32% +$35.5M 0.1% 197
2023
Q4
$103M Sell
116,821
-27,665
-19% -$22.8M 0.07% 251
2023
Q3
$119M Sell
144,486
-810
-0.6% -$637K 0.09% 194
2023
Q2
$104M Buy
145,296
+49,973
+52% +$38.5M 0.07% 222
2023
Q1
$78.3M Sell
95,323
-21,437
-18% -$16.2M 0.05% 282
2022
Q4
$84.2M Buy
116,760
+7,391
+7% +$5.45M 0.07% 265
2022
Q3
$75.3M Sell
109,369
-747
-0.7% -$470K 0.05% 275
2022
Q2
$65.1M Sell
110,116
-9,555
-8% -$6.21M 0.05% 314
2022
Q1
$83.6M Sell
119,671
-19,786
-14% -$12.5M 0.05% 322
2021
Q4
$88.1M Buy
139,457
+26,395
+23% +$16.2M 0.05% 355
2021
Q3
$68.4M Sell
113,062
-7,483
-6% -$4.65M 0.04% 408
2021
Q2
$67.3M Sell
120,545
-4,337
-3% -$2.2M 0.04% 425
2021
Q1
$59.1M Sell
124,882
-45,730
-27% -$22.3M 0.04% 430
2020
Q4
$82.4M Buy
170,612
+18,712
+12% +$10.1M 0.05% 335
2020
Q3
$85M Sell
151,900
-9,702
-6% -$5.88M 0.06% 282
2020
Q2
$101M Buy
161,602
+79,310
+96% +$45M 0.08% 211
2020
Q1
$40.2M Sell
82,292
-29,590
-26% -$12.2M 0.04% 446
2019
Q4
$42M Sell
111,882
-89,752
-45% -$30.2M 0.03% 581
2019
Q3
$55.9M Buy
201,634
+98,822
+96% +$29.2M 0.04% 405
2019
Q2
$32.2M Buy
102,812
+17,020
+20% +$5.67M 0.03% 651
2019
Q1
$35.2M Buy
85,792
+24,865
+41% +$10.2M 0.03% 539
2018
Q4
$22.8M Sell
60,927
-7,856
-11% -$2.88M 0.02% 751
2018
Q3
$27.8M Sell
68,783
-20,312
-23% -$7.73M 0.02% 652
2018
Q2
$30.7M Buy
89,095
+8,553
+11% +$2.67M 0.03% 560
2018
Q1
$27.7M Buy
80,542
+15,143
+23% +$5.27M 0.02% 617
2017
Q4
$24.6M Buy
65,399
+3,723
+6% +$1.51M 0.02% 732
2017
Q3
$27.6M Buy
61,676
+4,069
+7% +$1.94M 0.02% 649
2017
Q2
$28.3M Sell
57,607
-3,870
-6% -$1.69M 0.03% 602
2017
Q1
$23.8M Sell
61,477
-21,583
-26% -$8M 0.02% 680
2016
Q4
$30.5M Buy
83,060
+52,457
+171% +$19.9M 0.03% 559
2016
Q3
$12.3M Sell
30,603
-3,473
-10% -$1.39M 0.01% 946
2016
Q2
$11.9M Sell
34,076
-7,943
-19% -$3.06M 0.01% 935
2016
Q1
$15.1M Sell
42,019
-4,936
-11% -$2.03M 0.02% 752
2015
Q4
$25.5M Sell
46,955
-3,347
-7% -$1.81M 0.03% 629
2015
Q3
$23.4M Buy
50,302
+3,637
+8% +$1.95M 0.02% 646
2015
Q2
$23.8M Sell
46,665
-43,306
-48% -$21.1M 0.02% 695
2015
Q1
$40.6M Buy
89,971
+31,459
+54% +$13.3M 0.04% 430
2014
Q4
$24M Buy
58,512
+32,615
+126% +$12.8M 0.02% 707
2014
Q3
$9.34M Buy
25,897
+8,041
+45% +$2.7M 0.01% 1342
2014
Q2
$5.04M Sell
17,856
-2,417
-12% -$716K ﹤0.01% 1790
2014
Q1
$6.09M Sell
20,273
-6,140
-23% -$1.89M 0.01% 1548
2013
Q4
$7.27M Sell
26,413
-51,253
-66% -$14.7M 0.01% 1497
2013
Q3
$24.3M Sell
77,666
-11,335
-13% -$2.98M 0.02% 641
2013
Q2
$20M Buy
+89,001
New +$20.7M 0.02% 692

Other funds holding REGN

Citigroup's REGN Position: Q2 2026 in Review

Citigroup increased its Regeneron Pharmaceuticals (REGN) stake by 88% in Q2 2026, buying an estimated $110M and bringing the position to 346,637 shares worth $216M. The position accounts for 0.07% of the portfolio, ranked #240.

Citigroup first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Citigroup held 346,637 shares of Regeneron Pharmaceuticals worth $216M as of Q2 2026.
  • Citigroup bought 161,946 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $110M.
  • Regeneron Pharmaceuticals made up 0.07% of Citigroup's portfolio in Q2 2026, its #240 holding.
  • Citigroup first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.